Alnylam Pharmaceuticals (ALNY) vs Elanco Animal Health (ELAN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Elanco Animal Health (ELAN) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 15.7% versus a loss of 67.0%. Over five years, ELAN leads with a -14.8% price change compared with -23.7% for ALNY. Alnylam Pharmaceuticals is the larger company by market cap ($19.26 billion vs $12.87 billion), about 1.5 times the size.
On valuation, Alnylam Pharmaceuticals trades at a lower forward P/E (14.5x vs 19.9x for Elanco Animal Health). Alnylam Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.4% versus -4.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | ELAN |
|---|---|---|
| Share price | $143.82 | $25.74 |
| Market cap | $19.26B | $12.87B |
| 1-day change | -2.71% | -2.09% |
| YTD return | -63.83% | +13.74% |
| 1-year return | -67.04% | +15.69% |
| 5-year return | -23.72% | -14.82% |
| P/E ratio (TTM) | 7.26 | — |
| Forward P/E | 14.51 | 19.91 |
| EPS (TTM) | $19.80 | $-0.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.71B | $4.71B |
| Revenue growth (YoY) | +65.19% | +6.22% |
| Net income (latest FY) | $313.75M | $-232.00M |
| Gross margin | 81.77% | 54.99% |
| Operating margin | 13.51% | — |
| Net margin | 8.45% | -4.92% |
| 52-week high | $479.79 | $27.98 |
| 52-week low | $143.40 | $19.40 |
| Distance from 52-week high | -70.02% | -8.01% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +101.10% | +20.44% |
| Average volume | 2.09M | 5.32M |
| Shares outstanding | 133.94M | 499.83M |
| Employees | 2,500 | 9,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELAN has outperformed ALNY by 82.7 percentage points over the past year.
- Alnylam Pharmaceuticals is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -4.9 cents for Elanco Animal Health.
- Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs +6.22%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Elanco Animal Health
ELAN stock →Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
Health Care · Biotechnology: Pharmaceutical Preparations · 9,400 employees
ALNY vs ELAN FAQ
Which is bigger, Alnylam Pharmaceuticals or Elanco Animal Health?
Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $19.26B compared with $12.87B for Elanco Animal Health (ELAN).
Which stock has performed better over the past year, ALNY or ELAN?
ELAN returned +15.69% over the past 12 months, compared with -67.04% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Are Alnylam Pharmaceuticals and Elanco Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.